Forte Biosciences, Inc.
General ticker "FBRX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.7B (TTM average)
Forte Biosciences, Inc. follows the US Stock Market performance with the rate: 34.3%.
Estimated limits based on current volatility of 0.0%: low 76.92$, high 76.94$
Factors to consider:
- Total employees count: 19 as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Insufficient capital, Clinical trial failure, Regulatory and compliance, Market competition, Labor/talent shortage/retention
- Earnings for 6 months up through Q2 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [9.98$, 36.54$]
- 2026-12-31 to 2027-12-31 estimated range: [4.52$, 18.61$]
Financial Metrics affecting the FBRX estimates:
- Negative: with PPE of -5.7 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -12.68 <= 0.28
- Negative: negative Net income
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Investing cash flow per share per price, % of 9.03 > -0.64
- Positive: Shareholder equity ratio, % of 73.68 > 63.63
- Negative: negative Industry operating cash flow (median)
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term FBRX quotes
Long-term FBRX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $32.49MM | $36.60MM | $70.66MM |
| Operating Income | $-32.49MM | $-36.60MM | $-70.66MM |
| Non-Operating Income | $1.01MM | $1.12MM | $2.32MM |
| R&D Expense | $21.86MM | $20.71MM | $57.65MM |
| Income(Loss) | $-31.48MM | $-35.48MM | $-68.34MM |
| Taxes | $0.00MM | $0.00MM | $1.04MM |
| Net Income(Loss)* | $-31.48MM | $-35.48MM | $-69.38MM |
| Stockholders Equity | $35.31MM | $52.48MM | $60.99MM |
| Assets | $38.98MM | $61.56MM | $82.78MM |
| Operating Cash Flow | $-28.71MM | $-30.75MM | $-50.88MM |
| Capital expenditure | $0.09MM | $0.04MM | $0.12MM |
| Investing Cash Flow | $0.05MM | $-35.99MM | $36.23MM |
| Financing Cash Flow | $24.68MM | $51.86MM | $69.36MM |
| Earnings Per Share** | $-24.92 | $-12.17 | $-4.71 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.